3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Stomach Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Breast Neoplasms
3
Pancreatic Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Breast Neoplasms, Male
2
Vulvar Neoplasms
1
Vipoma
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Somatostatinoma
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pleural Effusion, Malignant
1
Parathyroid Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Unknown Primary
1
Lung Neoplasms
1
Interventions
Paclitaxel
328
Carboplatin
323
Bevacizumab
171
Gemcitabine
106
liposomal doxorubicin
104
pembrolizumab
101
Cyclophosphamide
96
Topotecan
94
olaparib
92
Cisplatin
92
niraparib
69
Docetaxel
57
Taxes
52
Doxorubicin
51
Drug Therapy
45
fludarabine
40
Filgrastim
39
Nivolumab
37
Magnetic Resonance Spectroscopy
34
Surveys and Questionnaires
33
Specimen Handling
33
Etoposide
32
Hyperthermic Intraperitoneal Chemotherapy
31
Blood Specimen Collection
29
Immunoglobulin G
27
Disulfides
27
Peripheral Blood Stem Cell Transplantation
26
Cytoreduction Surgical Procedures
25
Albumin-Bound Paclitaxel
25
durvalumab
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Interleukin-12
×
Gynecologic
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled